© 2021 © 2020 Genprex Inc. All Rights Reserved.
Genprex announced that it received notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule.
Genprex provides a clinical update and focus for its Oncoprex™ immunogene therapy program for 2020, prioritizing the development of Oncoprex in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC).
Mr. Rodney Varner, Chief Executive Officer of Genprex, will deliver an overview of the Company and provide updates on its product pipeline, including the recent Fast Track Designation received from the Food and Drug Administration for its Oncoprex™ immunogene therapy in combination with AstraZeneca’s Tagrisso®.
The study highlights the possibility that TUSC2 may also be effective in thyroid cancer therapy and adds to the growing body of research on TUSC2 beyond the non-small lung cell cancer indication the Company is initially pursuing
Capital raise follows recent Fast Track Designation by the FDA for Company’s Oncoprex™ imunogene therapy for NSCLC in combination therapy with AstraZeneca’s Tagrisso®
Genprex today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 7,620,000 shares of common stock, par value $0.001 per share at an offering price of $1.05 per share, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules.
Genprex announced that the FDA has granted Fast Track Designation for Genprex’s Oncoprex™ immunogene therapy in combination with EGFR inhibitor osimertinib for the treatment of non-small cell lung cancer (NSCLC) patients with EFGR mutations that progressed after treatment with osimertinib alone.
Genprex’s President and Chief Operating Officer, Julien Pham, MD, MPH, will lead the Company’s presentation and, along with Rodney Varner, the Company’s Chief Executive Officer, will be available for one-on-one investor meetings.
The company announced a registered direct offering of 3,167,986 shares of its common stock at a price to the public of $0.40 per share, for gross proceeds of approximately $1.26 million prior to deduction of commissions and offering expenses payable by Genprex.
The company announced a registered direct offering of 3,167,986 shares of its common stock at a price to the public of $0.40 per share, for gross proceeds of approximately $1.26 million prior to deduction of commissions and offering expenses payable by Genprex.